Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Pain and Headache Reports
Erschienen in: Current Pain and Headache Reports 9/2013

01.09.2013 | Secondary Headache (K Henry, Section Editor)

Migraine and Neurogenetic Disorders

verfasst von: Swati Sathe

Erschienen in: Current Pain and Headache Reports | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

In the current classification of headache disorders, headache attributable to genetic disorders is not classified separately, rather as headache attributed to cranial or cervical vascular disorder. The classification thus implies that a vascular pathology causes headache in these genetic disorders. Unquestionably, migraine is one of the prominent presenting features of several genetic cerebral small vessel diseases such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy, retinal vasculopathy with cerebral leukodystrophy, and hereditary infantile hemiparessis, retinal arteriolar tortuosity and leukoencephalopahty. Shared genetic features, increased susceptibility, and/or vascular endothelial dysfunction may play a role in pathogenesis of migraine. Common or overlapping pathways involving the responsible genes may provide insight regarding the pathophysiological mechanisms that can explain their comorbidity with migraine. This review focuses on clinical features of genetic vasculopathies. An independent category—migraine related to genetic disorders—should be considered to classify these disorders.
Literatur
1.
Goadsby PJ. The vascular theory of migraine – a great story wrecked by the facts. Brain. 2009;132:6–7.PubMedCrossRef
2.
Schoonman GG, van der Grond J, Kortmann C, et al. Migraine headache is not associated with cerebral or meningeal vasodilatation – a 3T magnetic resonance angiography study. Brain. 2008;131:2192–200.PubMedCrossRef
3.
Maassenvandenbrink A, Duncker DJ, Saxena PR. Migraine headache is not associated with cerebral or meningeal vasodilatation – a 3T magnetic resonance angiography study. Brain. 2009;132:e112.CrossRef
4.
Dreier JP, Kleeberg J, Alam M, et al. Endothelin-1-induced spreading depression in rats is associated with a microarea of selective neuronal necrosis. Exp Biol Med (Maywood). 2007;232:204–13.
5.
Brennan KC, Beltran-Parrazal L, López-Valdés HE, et al. Distinct vascular conduction with cortical spreading depression. J Neurophysiol. 2007;97:4143–51.PubMedCrossRef
6.
Porter A, Gladstone JP, Dodick DW. Migraine and white matter hyperintensities. Curr Pain Headache Rep. 2005;9:289–93.PubMedCrossRef
7.
Tzourio C, Benslamia L, Guillon B, Aïdi S, et al. Migraine and the risk of cervical artery dissection: a case–control study. Neurology. 2002;59:435–7.PubMedCrossRef
8.
Goadsby PJ. Neurovascular headache and a midbrain vascular malformation: evidence for a role of the brainstem in chronic migraine. Cephalalgia. 2002;22:107–11.PubMedCrossRef
9.
Kupersmith MJ, Vargas ME, Yashar A, et al. Occipital arteriovenous malformations: visual disturbances and presentation. Neurology. 1996;46:953–7.PubMedCrossRef
10.
Kurita H, Ueki K, Shin M, et al. Headaches in patients with radiosurgically treated occipital arteriovenous malformations. J Neurosurg. 2000;93:224–8.PubMedCrossRef
11.
Calabrese LH, Dodick DW, Schwedt TJ. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007;146:34–44.PubMedCrossRef
12.
Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9:689–701.PubMedCrossRef
13.
Dichgans M, Mayer M, Uttner I, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44:731–9.PubMedCrossRef
14.
• Chabriat H, Joutel A, Dichgans M, et al. Cadasil. Lancet Neurol. 2009;8:643–53. Summarizes current understanding of CADASIL and how it serves as a model for the more common forms of subcortical ischemic strokes and pure vascular dementia.PubMedCrossRef
15.
Razvi SS, Davidson R, Bone I, Muir KW. The prevalence of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) in the west of Scotland. J Neurol Neurosurg Psychiatry. 2005;76:739–41.PubMedCrossRef
16.
Desmond D, Moroney J, Lynch T, et al. The natural history of CADASIL a pooled analysis of previously published cases. Stroke. 1999;30:1230–3.PubMedCrossRef
17.
Vahedi K, Chabriat H, Levy C, et al. Migraine with aura and brain magnetic resonance imaging abnormalities in patients with CADASIL. Arch Neurol. 2004;61:1237–40.PubMedCrossRef
18.
Markus HS, Martin RJ, Simpson MA, et al. Diagnostic strategies in CADASIL. Neurology. 2002;59:1134–8.PubMedCrossRef
19.
Singhal S, Bevan S, Barrick T, et al. The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain. 2004;127:2031–8.PubMedCrossRef
20.
Verin M, Rolland Y, Landgraf F, et al. New phenotype of the cerebral autosomal dominant arteriopathy mapped to chromosome 19: Migraine as the prominent clinical feature. J Neurol Neurosurg Psychiatry. 1995;59:579–85.
21.
Schon F, Martin RJ, Prevett M, et al. “CADASIL coma”: An underdiagnosed acute encephalopathy. J Neurol Neurosurg Psychiatry. 2003;74:249–52.PubMedCrossRef
22.
Sathe S, DePeralta E, Pastores G, Kolodny EH. Acute confusional migraine may be a presenting feature of CADASIL. Headache. 2009;49:590–6.PubMedCrossRef
23.
Le Ber I, Carluer L, Derache N, et al. Unusual presentation of CADASIL with reversible coma and confusion. Neurology. 2002;59:1115–6.PubMedCrossRef
24.
Ducray F, Ritzenthaler T, Cho TH, et al. Acute headache followed by focal neuropsychological impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). J Stroke Cerebrovasc Dis. 2010;19:75–6.PubMedCrossRef
25.
Jouvent E, Mangin JF, Hervé D, et al. Cortical folding influences migraine aura symptoms in CADASIL. J Neurol Neurosurg Psychiatry. 2012;83:213–6.PubMedCrossRef
26.
Campolo J, De Maria R, Frontali M, et al. Impaired vasoreactivity in mildly disabled CADASIL patients. J Neurol Neurosurg Psychiatry. 2012;83:268–74.PubMedCrossRef
27.
Fujiwara Y, Mizuno T, Okuyama C, et al. Simultaneous impairment of intracranial and peripheral artery vasoreactivity in CADASIL patients. Cerebrovasc Dis. 2012;33:128–34.PubMedCrossRef
28.
Forteza AM, Brozman B, Rabinstein AA, Romano JG, Bradley WG. Acetazolamide for the treatment of migraine with aura in CADASIL. Neurology. 2010;57:2144–5.CrossRef
29.
Vahedi K, Taupin P, Djomby R, et al. Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomized placebo-controlled trial. J Neurol. 2002;249:206–11.PubMedCrossRef
30.
Donnini I, Nannucci S, Valenti R, et al. Acetazolamide for the prophylaxis of migraine in CADASIL: a preliminary experience. J Headache Pain. 2012;13:299–302.PubMedCrossRef
31.
Yonas H, Darby JM, Marks EC, Durham SR, Maxwell C. CBF measured by Xe-CT: approach to analysis and normal values. J Cereb Blood Flow Metab. 1991;11:716–25.PubMedCrossRef
32.
Eskey CJ, Sanelli PC. Perfusion imaging of cerebrovascular reserve. Neuroimaging Clin N Am. 1991;15:367–81.CrossRef
33.
Huang L, Yang Q, Zhang L, et al. Acetazolamide improves cerebral hemodynamics in CADASIL. J Neurol Sci. 2010;292:77–80.PubMedCrossRef
34.
Chabriat H, Pappata S, Ostergaard L, et al. Cerebral hemodynamics in CADASIL before and after acetazolamide challenge assessed with MRI bolus tracking. Stroke. 2000;31:1904–12.PubMedCrossRef
35.
Park SA, Yang CY, Choi SS, Kim WH. Assessment of cerebral hemodynamics to acetazolamide using brain perfusion SPECT in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Clin Nucl Med. 2011;36:158–9.PubMedCrossRef
36.
Van den Boom R, Lesnik Oberstein SA, Ferrari MD, Haan J, van Buchem MA. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: MR imaging findings at different ages – 3rd–6th decades. Radiology. 2003;229:683–90.PubMedCrossRef
37.
Lesnik Oberstein SA, van den Boom R, van Buchem MA, et al. Cerebral microbleeds in CADASIL. Neurology. 2001;57:1066–70.PubMedCrossRef
38.
• Joutel A. Pathogenesis of CADASIL Transgenic and knock-out mice to probe function and dysfunction of the mutated gene, Notch3, in the cerebrovasculature. Bioessays. 2011;33:73–80. Critical overview of mouse models of CADASIL, future directions, and further work that needs to be done to understand small vessel diseases.PubMedCrossRef
39.
Joutel A, Andreux F, Gaulis S, et al. The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest. 2000;105:597–605.PubMedCrossRef
40.
Opherk C, Duering M, Peters N, et al. CADASIL mutations enhance spontaneous multimerization of NOTCH3. Hum Mol Genet. 2009;18:2761–7.PubMedCrossRef
41.
Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383:707–10.PubMedCrossRef
42.
Peters N, Opherk C, Bergmann T, Castro M, et al. Spectrum of mutations in biopsy-proven CADASIL: implications for diagnostic strategies. Arch Neurol. 2005;62:1091–4.PubMedCrossRef
43.
Morrow D, Guha S, Sweeney C, et al. Notch and vascular smooth muscle cell phenotype. Circ Res. 2008;103:1370–82.PubMedCrossRef
44.
Grand MG, Kaine J, Fulling K, et al. Cerebroretinal vasculopathy. A new hereditary syndrome. Ophthalmology. 1988;95:649–59.PubMed
45.
Terwindt GM, Haan J, Ophoff RA, et al. Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud’s phenomenon. Brain. 1998;121:303–16.PubMedCrossRef
46.
Jen J, Cohen AH, Yue Q, et al. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology. 1997;49:1322–30.PubMedCrossRef
47.
Richard A, Van den Maagdenberg AM, et al. Truncations in the carboxyl-terminus of human 3'-5' DNA exonuclease TREX1 cause retinal vasculopathy with cerebral leukodystrophy. Nat Genet. 2007;39:1068–70.CrossRef
48.
Ophoff RA, DeYoung J, Service SK, et al. Hereditary vascular retinopathy, cerebroretinal vasculopathy, and hereditary endotheliopathy with retinopathy, nephropathy, and stroke map to a single locus on chromosome 3p21.1-p21.3. Am J Hum Genet. 2001;69:447–53.PubMedCrossRef
49.
Weil S, Reifenberger G, Dudel C, et al. Cerebroretinal vasculopathy mimicking a brain tumor: a case of a rare hereditary syndrome. Neurology. 1999;53:629–31.PubMedCrossRef
50.
Crow YJ, Hayward BE, Parmar R, et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat Genet. 2006;38:917–20.PubMedCrossRef
51.
Rice G, Newman WG, Dean J, et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet. 2007;80:811–5.PubMedCrossRef
52.
Lee-Kirsch MA, Chowdhury D, Harvey S, et al. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J Mol Med. 2007;85:531–7.PubMedCrossRef
53.
Lee-Kirsch MA, Gong M, Chowdhury D, et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet. 2007;39:1065–7.PubMedCrossRef
54.
Mazur DJ, Perrino FW. Excision of 3' termini by the Trex1 and TREX2 3' – >5' exonucleases. Characterization of the recombinant proteins. J Biol Chem. 2001;276:17022–9.PubMedCrossRef
55.
Morita M, Stamp G, Robins P, et al. Gene-targeted mice lacking the Trex1 (DNase III) 3' – >5' DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol. 2004;24:6719–27.PubMedCrossRef
56.
Martinvalet D, Zhu P, Lieberman J. Granzyme A: induces caspase independent mitochondrial damage, a required first step for apoptosis. Immunity. 2005;22:355–70.PubMedCrossRef
57.
Chowdhury D, Beresford PJ, Zhu P, et al. The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol Cell. 2006;23:133–42.PubMedCrossRef
58.
Yang YG, Lindahl T, Barnes DE. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell. 2007;131:873–86.PubMedCrossRef
59.
Vahedi K, Massin P, Guichard J-P, et al. Hereditary infantilehemiparesis, retinal arteriolar tortuosity, and leukoencephalopathy. Neurology. 2003;60:57–63.PubMedCrossRef
60.
Vahedi K, Boukobza M, Massin P, et al. Clinical and brain MRI follow-up study of a family with COL4A1 mutation. Neurology. 2007;69:1564–8.PubMedCrossRef
61.
Sibon I, Coupry I, Menegon P, et al. COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy and stroke. Ann Neurol. 2007;62:177–84.PubMedCrossRef
62.
Van Agtmael T, Schlotzer-Schrehardy U, McKie L, et al. Dominant mutations of Col4a1 result in basement membrane defects which lead to anterior segment dysgenesis and glomerulopathy. Hum Mol Genet. 2005;14:3161–8.PubMedCrossRef
63.
van der Knaap MS, Smit LM, et al. Neonatal porencephaly and adult stroke related to mutations in collagen IV A1. Ann Neurol. 2006;59:504–11.PubMedCrossRef
64.
de Vries LS, Koopman C, Groenendaal F, et al. COL4A1 mutation in two preterm siblings with antenatal onset of parenchymal hemorrhage. Ann Neurol. 2009;65:12–8.PubMedCrossRef
65.
Gould DB, Phalan FC, Breedveld GJ, et al. Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly. Science. 2005;308:1167–71.PubMedCrossRef
66.
Gould DB, Phalan FC, van Mil SE, et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med. 2006;354:1489–96.PubMedCrossRef
67.
Mine M, Tournier-Lasserve E. Intracerebral hemorrhage and COL4A1 mutations, from preterm infants to adult patients. Ann Neurol. 2009;65:1–2.PubMedCrossRef
68.
• Stam AH, Haan J, van den Maagdenberg AM, et al. Migraine and genetic and acquired vasculopathies. Cephalalgia. 2009;29:1006–17. Review on genetic and acquired vasculopathies associated with migraine, as well as how genetic and acquired vascular mechanisms might be involved in migraine.PubMedCrossRef
69.
Schwaag S, Evers S, Schirmacher A, et al. Genetic variants of the NOTCH3 gene in migraine– a mutation analysis and association study. Cephalalgia. 2006;26:158–61.PubMedCrossRef
70.
Borroni B, Brambilla C, Liberini P, et al. Investigating the association between Notch3 polymorphism and migraine. Headache. 2006;46:317–21.PubMedCrossRef
71.
Peters N, Freilinger T, Opherk C, Pfefferkorn T, Dichgans M. Enhanced L-arginine-induced vasoreactivity suggests endothelial dysfunction in CADASIL. J Neurol. 2008;255:1203–8.PubMedCrossRef
72.
Liem MK, Lesnik Oberstein SA, Haan J, et al. Reactivity C is a main determinant of white matter hyperintensity progression in CADASIL. AJNR Am J Neuroradiol. 2009;30:1244–7.PubMedCrossRef
73.
Ruchoux MM, Guerouaou D, Vandenhaute B, et al. Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Acta Neuropathol. 1995;89:500–12.PubMedCrossRef
74.
Dreier JP, Kleeberg J, Petzold G, et al. Endothelin-1 potently induces Leao’s cortical spreading depression in vivo in the rat: a model for an endothelial trigger of migrainous aura? Brain. 2002;125:102–12.PubMedCrossRef
75.
Goto Y, Horai S, Matsuoka T, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. Neurology. 1992;42:545–50.PubMedCrossRef
76.
Hirano M, Ricci E, Koenigsberger MR, Defendini R, Pavlakis SG, De Vivo DC, et al. MELAS: an original case and clinical criteria for diagnosis. Neuromusc Disord. 1992;2:125–35.PubMedCrossRef
77.
• Sparaco M, Feleppa M, Lipton RB, et al. Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia. 2006;26:361–72. Review of morphological, biochemical, imaging, and genetic studies which bear on the hypothesis that migraine may be related to mitochondrial dysfunction.PubMedCrossRef
78.
Koo B, Becker LE, Chuang S, Merante F, Robinson BH, MacGregor D, et al. Mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes (MELAS): clinical, radiological, pathological, and genetic observations. Ann Neurol. 1993;34:25–32.PubMedCrossRef
79.
Montagna P, Galassi R, Medori R, Govoni E, Zeviani M, Di Mauro S, et al. MELAS syndrome: characteristic migrainous and epileptic features and maternal transmission. Neurology. 1988;38:751–4.PubMedCrossRef
80.
Ciafaloni E, Ricci E, Shanske S, Moraes CT, Silvestri G, Hirano M, et al. MELAS: clinical features, biochemistry, and molecular genetics. Ann Neurol. 1992;31:391–8.PubMedCrossRef
81.
Silvestri G, Ciafaloni E, Santorelli FM, Shanske S, Servidei S, Graf WD, et al. Clinical features associated with the A–>G transition at nucleotide 8344 of mtDNA (‘MERRF mutation’). Neurology. 1993;43:1200–6.PubMedCrossRef
82.
Hammans SR, Sweeney MG, Brockington M, Lennox GG, Lawton NF, Kennedy CR, et al. The mitochondrial DNA transfer RNA (Lys) A–>G (8344) mutation and the syndrome of myoclonic epilepsy with ragged red fibres (MERRF). Relationship of clinical phenotype to proportion of mutant mitochondrial DNA. Brain. 1993;116:617–32.PubMedCrossRef
83.
Huoponen K. Leber hereditary optic neuropathy: clinical and molecular genetic findings. Neurogenetics. 2001;3:119–25.PubMedCrossRef
84.
Haan J, Terwindt GM, Maassen JA, Hart LM, Frants RR, Ferrari MD. Search for mitochondrial DNA mutations in migraine subgroups. Cephalalgia. 1999;19:20–2.PubMedCrossRef
85.
Schoenen J. Deficient habituation of evoked cortical potentials in migraine: a link between brain biology, behavior and trigeminovascular activation? Biomed Pharmacother. 1996;50:71–8.PubMedCrossRef
86.
Phelps ME, Kuhl DE. Metabolic mapping of the brain’s response to visual stimulation: studies in humans. Science. 1981;211:1445–8.PubMedCrossRef
87.
Fox PT, Raichle ME, Mintum MA, Dence C. Nonoxidative glucose consumption during focal physiological neural activity. Science. 1988;241:462–4.PubMedCrossRef
88.
Prichard JW, Rothmann DL, Novotny E, Petroff OAC, Kuwabara T, Avison M, et al. Lactate rise detected by 1H NMR in human visual cortex during physiologic stimulation. Proc Natl Acad Sci USA. 1991;88:5829–31.PubMedCrossRef
89.
Sacco S, Carolei A. Migraine attributed to genetic disorder. Funct Neurol. 2007;22:117–8.PubMed
Metadaten
Titel
Migraine and Neurogenetic Disorders
verfasst von
Swati Sathe
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Current Pain and Headache Reports / Ausgabe 9/2013
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-013-0360-9

Weitere Artikel der Ausgabe 9/2013

Current Pain and Headache Reports 9/2013 Zur Ausgabe

Myofascial Pain (R Gerwin, Section Editor)

Myofascial Trigger Point Therapy: Laser Therapy and Dry Needling

Neuropathic Pain (E Eisenberg, Section Editor)

Update on Neuropathic Pain Treatment: Ion Channel Blockers and Gabapentinoids

Neuropathic Pain (E Eisenberg, Section Editor)

Conditioned Pain Modulation: A Predictor for Development and Treatment of Neuropathic Pain

Neuropathic Pain (E Eisenberg, Section Editor)

Review of Neuropathic Pain Screening and Assessment Tools

Fibromyalgia (M Peres, Section Editor)

Fibromyalgia Comorbid with Anxiety Disorders and Depression: Combined Medical and Psychological Treatment

Migraine (R Cowan, Section Editor)

Why Does Vomiting Stop a Migraine Attack?

Neu im Fachgebiet AINS

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise